Evotec AG has launched a new drug discovery collaboration involving artificial intelligence – this time to identify small molecules to treat rare hereditary metabolic diseases. The partner is Immuneering Corp of Cambridge, Massachusetts which is 51% controlled by Teva Pharmaceutical Industries Ltd.
Immuneering applies AI and other advanced algorithms to data derived from high throughput screening. The goal is to identify molecular structures that could form the basis of new medicines.